Indoco Remedies Ltd received final approval from USFDA for its Abbreviated New Drug Application for Rivaroxaban Tablets USP (2.5 mg, 10 mg, 15 mg, and 20 mg) on August 13, 2025, allowing it to market a generic version of Xarelto Tablets.
AI Assistant
Indoco Remedies Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.